Qiagen to acquire Nextal Biotechnology

Qiagen has agreed to buy Canada's Nextal Biotechnology for up to $14.2 million, with $9.7 million in cash and the rest paid out according to predetermined milestones. Nextal has developed products that "simplify the process of sample preparation of proteins for subsequent crystallographic analysis."

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.